論文 - 詳細
| RRC ID | 64280 |
|---|---|
| 著者 | Yasukawa Y, Hattori N, Iida N, Takeshima H, Maeda M, Kiyono T, Sekine S, Seto Y, Ushijima T. |
| タイトル | SAA1 is upregulated in gastric cancer-associated fibroblasts possibly by its enhancer activation. |
| ジャーナル | Carcinogenesis |
| Abstract |
Cancer-associated fibroblasts (CAFs) tend to have tumor-promoting capacity, and can provide therapeutic targets. Even without cancer cells, CAF phenotypes are stably maintained, and DNA methylation and H3K27me3 changes have been shown to be involved. Here, we searched for a potential therapeutic target in primary CAFs from gastric cancer and a mechanism for its dysregulation. Expression microarray using eight CAFs and seven non-CAFs (NCAFs) revealed that serum amyloid A1 (SAA1), which encodes an acute phase secreted protein, was second most upregulated in CAFs, following IGF2. Conditioned medium (CM) derived from SAA1-overexpressing NCAFs was shown to increase migration of gastric cancer cells compared with that from control NCAFs, and its tumor-promoting effect was comparable to that of CM from CAFs. In addition, increased migration of cancer cells by CM from CAFs was mostly canceled with CM from CAFs with SAA1 knockdown. Chromatin immunoprecipitation (ChIP)-quantitative PCR showed that CAFs had higher levels of H3K27ac, an active enhancer mark, in the promoter and the two far upstream regions of SAA1 than NCAFs. Also, BET bromodomain inhibitors, JQ1 and mivebresib, decreased SAA1 expression and tumor-promoting effects in CAFs, suggesting SAA1 upregulation by enhancer activation in CAFs. Our present data showed that SAA1 is a candidate therapeutic target from gastric CAFs and indicated that increased enhancer acetylation is important for its overexpression. |
| 巻・号 | 42(2) |
| ページ | 180-189 |
| 公開日 | 2021-2-25 |
| DOI | 10.1093/carcin/bgaa131 |
| PII | 6025409 |
| PMID | 33284950 |
| MeSH | Acetylation Azepines / pharmacology Azepines / therapeutic use Cancer-Associated Fibroblasts / drug effects Cancer-Associated Fibroblasts / metabolism* Cell Cycle Proteins / antagonists & inhibitors Cell Cycle Proteins / metabolism Cell Line, Tumor Cell Movement / drug effects Cell Movement / genetics Cell Proliferation / drug effects Cell Proliferation / genetics Culture Media, Conditioned / metabolism Enhancer Elements, Genetic Gastrectomy Gastric Mucosa / cytology Gastric Mucosa / pathology Gastric Mucosa / surgery Gene Expression Profiling Gene Expression Regulation, Neoplastic / drug effects Gene Knockdown Techniques Humans Primary Cell Culture Pyridones / pharmacology Pyridones / therapeutic use Serum Amyloid A Protein / genetics* Serum Amyloid A Protein / metabolism Signal Transduction / drug effects Signal Transduction / genetics Stomach Neoplasms / drug therapy Stomach Neoplasms / pathology* Stomach Neoplasms / surgery Sulfonamides / pharmacology Sulfonamides / therapeutic use Transcription Factors / antagonists & inhibitors Transcription Factors / metabolism Triazoles / pharmacology Triazoles / therapeutic use Up-Regulation |
| IF | 4.603 |
| オルトメトリクス指標 |
オルトメトリクス指標項目
|
| 最多言及媒体 | X(Twitter) |
| 各媒体での言及数の合計 | 1 |
| 過去6か月間でのオルトメトリクス指標の変動値 | 0.0 |
| リソース情報 | |
| 遺伝子材料 | CSII-CMV-RfA (RDB04386) |